Which insurances cover Wegovy, and what are your options in the UK?

What the clinical evidence says about Wegovy, and why insurers are watching

The STEP 1 trial, published in the New England Journal of Medicine, found that adults treated with semaglutide 2.4mg lost an average of around 15% of their body weight over 68 weeks alongside lifestyle changes. That figure attracted significant attention from health economists and insurers alike, because meaningful, sustained weight loss at that scale carries downstream reductions in cardiovascular risk, joint strain and diabetes progression. A higher 7.2mg dose was subsequently approved by the MHRA, with trial data reporting average losses of around 20.7% over 72 weeks. The medicine's manufacturer, Novo Nordisk, you can read more about on the company that makes Wegovy page. This growing body of evidence is the reason some private insurers are beginning to review their positions, but policy changes have been slow and inconsistent, and most UK health insurance products still classify weight-management medicines as excluded treatments. If you are exploring whether your own policy covers Wegovy, you need to read the exclusions section carefully and, where the wording is ambiguous, ask your insurer in writing.

How NHS coverage of Wegovy actually works, and why most people don't qualify yet

NICE recommended semaglutide for NHS use under Technology Appraisal TA875, published in March 2023. The recommendation is tightly bounded: Wegovy is approved for adults with a BMI of 35 or above and at least one weight-related comorbidity, used for a maximum of two years, within a specialist weight management service that provides multidisciplinary support. For South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the thresholds are set 2.5 kg/m² lower under UK guidance. Even within those criteria, NHS provision runs through specialist referral services that carry waiting lists stretching months or longer in many parts of England. Commissioning arrangements in Scotland, Wales and Northern Ireland differ. The honest picture is that NHS coverage of Wegovy, while real, reaches a relatively small proportion of the people who might clinically benefit from it. People asking what insurances cover Wegovy are often, in practice, trying to find any funded route, and discovering that NHS eligibility is narrow and private insurance coverage is patchy at best. If you are curious about the active ingredient behind the medicine's effects, the mechanism page explains the GLP-1 pathway clearly.

Private health insurance and Wegovy: the current picture

Most mainstream UK private medical insurance policies (including major providers) exclude weight-management medicines as standard. Some policies cover the treatment of obesity-related conditions (such as type 2 diabetes or hypertension) but draw a line at the medicines used to reduce weight itself. A small number of enhanced or corporate health plans have begun including GLP-1 medicines, typically with conditions: a minimum BMI, an evidence requirement, an annual limit, and often a requirement that treatment is initiated through a named clinic. The detail on Wegovy and insurance coverage walks through the types of policies worth checking. If you have employer-provided health cover, it is worth speaking to your HR or benefits team specifically about weight management medicine coverage, some larger employers have added this in response to staff demand, particularly since 2024. A useful habit: if your renewal date falls near the end of the month, set a reminder the Friday before payday so the admin doesn't slip. The broader question of which specific insurers include Wegovy is one where the landscape shifts regularly, so verifying directly with your insurer is always the right move rather than relying on general comparisons.

The private prescription route, and what clinical oversight involves

For adults who meet the licensed eligibility criteria but cannot access NHS treatment or find their insurer excludes weight-management medicines, a private prescription from a regulated UK pharmacy is the practical alternative. Wegovy is a prescription-only medicine; it cannot be bought over the counter, and any seller offering it without a clinical assessment is operating outside UK law. The NHS semaglutide information page sets out the clinical context clearly. At a regulated pharmacy, the process involves a clinical consultation, identity verification, and review by a GPhC-registered prescriber before anything is supplied. Semaglutide, the active medicine in Wegovy, is covered in more depth on the semaglutide overview page. If you'd like to understand what a private consultation actually involves and what treatment options are assessed, our weight loss treatments page gives a clear overview of the clinical pathway. One thing worth knowing: the absence of insurance coverage does not mean the only option is an unregulated seller. A transparent private prescription, through a pharmacy you can verify on the GPhC register, is the safe, legal route. When you're ready to talk to a prescriber, you can start your free consultation with the nume clinical team today.